EUVIMEDEUVIMED entdecken
Crossref

Dihydroartemisinin inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53

Huijuan Ling, Jing Tang, Yayu Zhu, Ke Niu, Ping Qiu, Renjie Chen, Liwen Chen

Biochemical Pharmacology · 2025-11 · 241 · 117191

DOI: 10.1016/j.bcp.2025.117191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025-11. Verfasst von Huijuan Ling und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Teaching and Research Section, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Artemisinins, Carcinoma, Non-Small-Cell Lung, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Scientific Research Foundation of Education Department of Anhui Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antimalarial agent Dihydroartemisinin (DHA) has significant potential for drug repurposing for cancer therapy including non-small cell lung cancer (NSCLC). However, its underlying anti-tumor mechanisms remain to be elucidated. In this study, we demonstrated that DHA suppressed the mouse double minute 2 (MDM2) in A549 and H1299 cells, whereas MDM2 overexpression effectively restored DHA's inhibition on both NSCLC cell lines. We showed that DHA acted via phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and Janus kinase (JAK)/Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathways to inhibit MDM2 expression. Being an established MDM2 target, p53 was significantly upregulated in p53 wild-type A549 cells upon DHA treatment both in vitro and in vivo; however, the mediating role of MDM2 in DHA's suppression on NSCLC is independent of p53 since DHA-treated si-p53 A549 cells had comparable colony formation capacity compared with that of si-Control. The anti-tumor effects of DHA bypass p53 was further implicated using H1299, a cell line which is MDM2-overexpressed but p53-null. Instead, c-Myc was observed to mediate the effects of DHA/MDM2 axis as co-immunoprecipitation (Co-IP) analysis showed the direct protein interaction between MDM2 and c-Myc, both were substantially reduced upon DHA treatment. Furthermore, c-Myc overexpression effectively restored DHA's suppression on proliferation, and DHA's induction on apoptosis of A549 and H1299 cells. Finally, immunohistochemistry (IHC) analysis showed that in vivo administration of DHA substantially reduced both MDM2 and c-Myc expression in xenograft murine models. Taken together, our results demonstrated that DHA inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2ArtemisininsCarcinoma, Non-Small-Cell LungTumor Suppressor Protein p53Lung NeoplasmsProto-Oncogene Proteins c-mycHumansAnimalsMiceMice, NudeCell Line, TumorXenograft Model Antitumor AssaysSignal TransductionA549 CellsAntineoplastic AgentsMice, Inbred BALB C

Stichwörter der Autor:innen

DihydroartemisininMDM2NSCLCP53c-Myc

Substanzen

artenimolProto-Oncogene Proteins c-mdm2ArtemisininsTumor Suppressor Protein p53MDM2 protein, humanProto-Oncogene Proteins c-mycMYC protein, humanAntineoplastic AgentsTP53 protein, human

Autor:innen und Institutionen

  • Laboratory Medicine Teaching and Research Section, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
  • Laboratory Medicine Teaching and Research Section, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Department of Blood Transfusion, The Second Affiliated Hospital of Anhui Medical Univer…

Förderung

  • Scientific Research Foundation of Education Department of Anhui Province of China

Zitieren

APA

Ling, H., Tang, J., Zhu, Y., Niu, K., Qiu, P., Chen, R., & Chen, L. (2025). Dihydroartemisinin inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53. Biochemical Pharmacology, 241, 117191. https://doi.org/10.1016/j.bcp.2025.117191

Vancouver

Ling H, Tang J, Zhu Y, Niu K, Qiu P, Chen R, et al. Dihydroartemisinin inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53. Biochemical Pharmacology. 2025;241:117191. doi:10.1016/j.bcp.2025.117191

BibTeX
@article{Ling2025,
  author = {Ling, Huijuan and Tang, Jing and Zhu, Yayu and Niu, Ke and Qiu, Ping and Chen, Renjie and Chen, Liwen},
  title = {Dihydroartemisinin inhibits NSCLC by targeting MDM2/c-Myc axis independent of p53},
  journal = {Biochemical Pharmacology},
  year = {2025},
  volume = {241},
  pages = {117191},
  doi = {10.1016/j.bcp.2025.117191}
}
Kostenlos starten →